234 related articles for article (PubMed ID: 37558549)
1. The NRF2/Keap1 pathway as a therapeutic target in inflammatory bowel disease.
Geertsema S; Bourgonje AR; Fagundes RR; Gacesa R; Weersma RK; van Goor H; Mann GE; Dijkstra G; Faber KN
Trends Mol Med; 2023 Oct; 29(10):830-842. PubMed ID: 37558549
[TBL] [Abstract][Full Text] [Related]
2. The Nrf2 in the pathophysiology of the intestine: Molecular mechanisms and therapeutic implications for inflammatory bowel diseases.
Piotrowska M; Swierczynski M; Fichna J; Piechota-Polanczyk A
Pharmacol Res; 2021 Jan; 163():105243. PubMed ID: 33080322
[TBL] [Abstract][Full Text] [Related]
3. Role of oxidative stress in pathophysiology of rheumatoid arthritis: insights into NRF2-KEAP1 signalling.
Kaur G; Sharma A; Bhatnagar A
Autoimmunity; 2021 Nov; 54(7):385-397. PubMed ID: 34415206
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in Understanding Nrf2 Agonism and Its Potential Clinical Application to Metabolic and Inflammatory Diseases.
Kim MJ; Jeon JH
Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269986
[TBL] [Abstract][Full Text] [Related]
5. The Role of NRF2/KEAP1 Signaling Pathway in Cancer Metabolism.
Song MY; Lee DY; Chun KS; Kim EH
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922165
[TBL] [Abstract][Full Text] [Related]
6. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
[TBL] [Abstract][Full Text] [Related]
7. The Keap1-Nrf2 System: A Mediator between Oxidative Stress and Aging.
Yu C; Xiao JH
Oxid Med Cell Longev; 2021; 2021():6635460. PubMed ID: 34012501
[TBL] [Abstract][Full Text] [Related]
8. Nuclear factor erythroid 2-related factor 2 (Nrf2) as a potential therapeutic target for vitiligo.
Lin X; Meng X; Song Z; Lin J
Arch Biochem Biophys; 2020 Dec; 696():108670. PubMed ID: 33186606
[TBL] [Abstract][Full Text] [Related]
9. Management of COVID-19-induced cytokine storm by Keap1-Nrf2 system: a review.
Singh E; Matada GSP; Abbas N; Dhiwar PS; Ghara A; Das A
Inflammopharmacology; 2021 Oct; 29(5):1347-1355. PubMed ID: 34373972
[TBL] [Abstract][Full Text] [Related]
10. The Keap1/Nrf2-ARE Pathway as a Pharmacological Target for Chalcones.
de Freitas Silva M; Pruccoli L; Morroni F; Sita G; Seghetti F; Viegas C; Tarozzi A
Molecules; 2018 Jul; 23(7):. PubMed ID: 30037040
[TBL] [Abstract][Full Text] [Related]
11. Recent progress and applications of small molecule inhibitors of Keap1-Nrf2 axis for neurodegenerative diseases.
Wang J; Cao Y; Lu Y; Zhu H; Zhang J; Che J; Zhuang R; Shao J
Eur J Med Chem; 2024 Jan; 264():115998. PubMed ID: 38043492
[TBL] [Abstract][Full Text] [Related]
12. NF-κB and Keap1 Interaction Represses Nrf2-Mediated Antioxidant Response in Rabbit Hemorrhagic Disease Virus Infection.
Hu B; Wei H; Song Y; Chen M; Fan Z; Qiu R; Zhu W; Xu W; Wang F
J Virol; 2020 May; 94(10):. PubMed ID: 32161178
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of miR-200a protects cardiomyocytes against hypoxia-induced apoptosis by modulating the kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 signaling axis.
Sun X; Zuo H; Liu C; Yang Y
Int J Mol Med; 2016 Oct; 38(4):1303-11. PubMed ID: 27573160
[TBL] [Abstract][Full Text] [Related]
14. Impaired antioxidant KEAP1-NRF2 system in amyotrophic lateral sclerosis: NRF2 activation as a potential therapeutic strategy.
Bono S; Feligioni M; Corbo M
Mol Neurodegener; 2021 Oct; 16(1):71. PubMed ID: 34663413
[TBL] [Abstract][Full Text] [Related]
15. Hydrogen Sulfide Alleviates Liver Injury Through the S-Sulfhydrated-Kelch-Like ECH-Associated Protein 1/Nuclear Erythroid 2-Related Factor 2/Low-Density Lipoprotein Receptor-Related Protein 1 Pathway.
Zhao S; Song T; Gu Y; Zhang Y; Cao S; Miao Q; Zhang X; Chen H; Gao Y; Zhang L; Han Y; Wang H; Pu J; Xie L; Ji Y
Hepatology; 2021 Jan; 73(1):282-302. PubMed ID: 32219872
[TBL] [Abstract][Full Text] [Related]
16.
Hu X; Mu L; Zhu L; Chang X; Nie L; Wang L; Li G
Mol Med Rep; 2021 Sep; 24(3):. PubMed ID: 34278476
[TBL] [Abstract][Full Text] [Related]
17. The principal molecular mechanisms behind the activation of Keap1/Nrf2/ARE pathway leading to neuroprotective action in Parkinson's disease.
Chakkittukandiyil A; Sajini DV; Karuppaiah A; Selvaraj D
Neurochem Int; 2022 Jun; 156():105325. PubMed ID: 35278519
[TBL] [Abstract][Full Text] [Related]
18. The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update.
Lu MC; Ji JA; Jiang ZY; You QD
Med Res Rev; 2016 Sep; 36(5):924-63. PubMed ID: 27192495
[TBL] [Abstract][Full Text] [Related]
19. Activation of kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor 2/antioxidant response element pathway by curcumin enhances the anti-oxidative capacity of corneal endothelial cells.
Guo SP; Chang HC; Lu LS; Liu DZ; Wang TJ
Biomed Pharmacother; 2021 Sep; 141():111834. PubMed ID: 34153850
[TBL] [Abstract][Full Text] [Related]
20. Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression.
Nezu M; Suzuki N; Yamamoto M
Am J Nephrol; 2017; 45(6):473-483. PubMed ID: 28502971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
